WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561270
CAS#: 251356-32-8
Description: SU9518 is a tyrosine kinase inhibitor with PDGFRα specificity. SU9518 can inhibit the development of proliferative vitreoretinopathy (PVR) in fibroblast and Müller cell rabbit models.
Hodoodo Cat#: H561270
Name: SU9518
CAS#: 251356-32-8
Chemical Formula: C18H17BrN2O3
Exact Mass: 388.04
Molecular Weight: 389.250
Elemental Analysis: C, 55.54; H, 4.40; Br, 20.53; N, 7.20; O, 12.33
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SU9518; SU 9518; SU-9518; 5-Br-SU6668; 5 Br SU6668; 5BrSU6668
IUPAC/Chemical Name: 3-[5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]propionic acid
InChi Key: CQXPYMNBBOWLME-ZSOIEALJSA-N
InChi Code: InChI=1S/C18H17BrN2O3/c1-9-12(4-6-17(22)23)10(2)20-16(9)8-14-13-7-11(19)3-5-15(13)21-18(14)24/h3,5,7-8,20H,4,6H2,1-2H3,(H,21,24)(H,22,23)/b14-8-
SMILES Code: O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C\2C=C(Br)C=C3)=O)=C1C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 389.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Velez G, Weingarden AR, Lei H, Kazlauskas A, Gao G. SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models. Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1392-7. doi: 10.1167/iovs.12-10320. PubMed PMID: 23341018; PubMed Central PMCID: PMC3597189.
2: Li M, Ping G, Plathow C, Trinh T, Lipson KE, Hauser K, Krempien R, Debus J, Abdollahi A, Huber PE. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer. 2006 Mar 24;6:79. PubMed PMID: 16556328; PubMed Central PMCID: PMC1458351.
3: Dadrich M, Nicolay NH, Flechsig P, Bickelhaupt S, Hoeltgen L, Roeder F, Hauser K, Tietz A, Jenne J, Lopez R, Roehrich M, Wirkner U, Lahn M, Huber PE. Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis. Oncoimmunology. 2015 Dec 29;5(5):e1123366. doi: 10.1080/2162402X.2015.1123366. eCollection 2016 May. PubMed PMID: 27467922; PubMed Central PMCID: PMC4910723.
4: Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J, Wang X, Sun L, Tang C, McMahon G, Lipson KE. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res. 2001 Mar 30;88(6):630-6. PubMed PMID: 11282898.
5: Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 2013 Aug;62(8):2870-8. doi: 10.2337/db12-1619. Epub 2013 Jul 8. PubMed PMID: 23835340; PubMed Central PMCID: PMC3717875.
6: Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005 Mar 21;201(6):925-35. PubMed PMID: 15781583; PubMed Central PMCID: PMC2213091.